$MEDS

DataMeds AI (NASDAQ:MEDS) and Tollo Health launched Galectovid, a medical food for viral infections, at 50% off for the 2026 Cold & Flu Season. Available online at TolloHealth.Shop and CorexaRx.com, Galectovid targets galectin-1 and galectin-3 proteins. The company expects consumer satisfaction and plans to expand research through physician relationships.

DataMeds AI (NASDAQ: MEDS) launched Galectovid, a medical food for viral infections, at 50% off during its #Back2School50% campaign. The product is available OTC via Tollo Health and Corexa Pharmacy. Galectovid targets galectin-1 and galectin-3 proteins and is classified as a medical food with GRAS-listed ingredients.

DataMeds AI (MEDS) and Datavault AI (DVLT) expanded their tech licensing deal, allowing Datavault's data monetization tech in DataMeds' healthcare apps. Datavault will receive 19.9% of DataMeds' common stock. The deal targets the growing healthcare data market, with DataMeds launching its 'Health Lives Here' app in 2026. DataMeds also rebranded and started trading under the new ticker 'MEDS'.

DataMeds AI, Inc. (MEDS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 DataMeds AI Reports Second Quarter 2026 Financials and Provides Business Update ■ Health Lives Here app launch with NFL Alumni Health expected in September 2026 ■ Revenues grew 14% reaching $1.779M in Q2/26, beating management projections ■ Corporate name change from

DataMeds AI, Inc. (NASDAQ:MEDS) said its board set Sept. 9, 2026 as the payment date for a previously announced distribution of Dream Bowl Meme Coin I tokens to record holders as of Aug. 7, 2026. Holders will receive 50 tokens per share. The company plans to distribute about 153,631,650 tokens and list them on Biconomy in Q3 2026.

DataMEDS AI, Inc. (MEDS) filed a Notification of Late Filing for its Q2 2026 Form 10-Q, saying it will miss the original Aug. 14, 2026 due date for the quarter ended June 30, 2026. The company cited needing additional time to complete financial statements and disclosures, and expects to file within the five-day Rule 12b-25 extension.

DataMeds AI (NASDAQ:MEDS) said its Corexa Health pharmacy division, Corexa Pharmacy, has completed the CorexaRx.com store integration into the Health Lives Here app and added access to oral GLP-1 drugs and injectable GLP-1s. It reported July 2026 revenue above $600,000, stabilizing a run rate above $7 million annually, and said Forzet, Galectovid, and Tollovid are now available.

DataMeds AI, Inc. (NASDAQ:MEDS) reiterated that Aug. 7, 2026 is the record date for a 50:1 Dream Bowl Meme Coin token to DataMeds common shares dividend ratio, according to the company. The token is listed on Biconomy, and the company said it intends to pursue fail-to-deliver notices aggressively.

DataMeds AI (MEDS) said it signed an amended letter of intent to gain control of Tollo Health, license QOLPOM-related IP from EOS Technology Holdings and Scilex, and expand its Datavault AI Health license. Consideration is in common stock only. EOS, Scilex, Datavault AI and HealthBridge Advisors are expected to hold about 84.6% post-closing, Fortitude about 5%, subject to adjustments. Closing depends on definitive deals, financing, approvals and Nasdaq.

DataMeds AI, Inc. (MEDS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. As previously disclosed on May 20, 2026, DataMEDS AI, Inc. (formerly Wellgistics Health, Inc.) (the “Company”) entered into a Fully Binding Term Sheet, dated May 18, 2026, with EOS Technology Holdings, Inc. (“EOS”), Scilex Ho